High incidence of intact or fragmented immunoglobulin in urine of patients with multiple myeloma

Leukemia and Lymphoma

Volumn 56, Issue 12, 2015, Pages 3348-3356

  Kraj, Maria ^a   Kruk, Barbara ^a   Lech Maranda, Ewa ^a,b   Warzocha, Krzysztof ^a   Prochorec Sobieszek, Monika ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Free light chains; intact immunoglobulin; multiple myeloma; urine immunoglobulin

Indexed keywords

BENCE JONES PROTEIN; FREE LIGHT CHAIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN FRAGMENT;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; ELECTROPHORESIS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY FAILURE; KIDNEY FUNCTION; LASER NEPHELOMETER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEINURIA; QUANTITATIVE ANALYSIS; URINALYSIS; URINE; URINE LEVEL; VERY ELDERLY; BLOOD; CANCER STAGING; COMPLICATION; FOLLOW UP; INCIDENCE; KIDNEY FUNCTION TEST; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULINS; INCIDENCE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROTEINURIA; SURVIVAL ANALYSIS;

EID: 84948655079     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1037753     Document Type: Article

References (46)

1. Sarav M, Wang Y, Hack BK, et al. Renal FcRN reclaims albumin but facilitates elimination of IgG. J Am Soc Nephrol 2009; 20: 1941-1952.
2. Ludwig H, Young P, Milosavljevic D, et al. Intact immunoglobulin or fragments thereof can be detected in urine in a proportion of patients with multiple myeloma and are associated with reduced survival at presentation. 54th American Society of Hematology Annual Meeting Atlanta, GA, USA, 8 December 2012. Abstract 1828.
3. Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009; 55: 1517-1522.
4. Snozek CI, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008; 22: 1933-1937.
5. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-680.
6. Hill PG, Forsyth JM, Rai B, et al. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 2006; 52: 1743-1748.
7. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007; 137: 240-243.
8. Drayson MT, Carr Smith HD. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med 2012; 50: 587-588.
9. Harding SJ, Mead GP, Bradwell AR, et al. Serum free light chain immunoassay as an adjunct to serum protein electrophoresis and immunofixation electrophoresis in the detection of multiple myeloma and other B-cell malignancies. Clin Chem Lab Med 2009; 47: 302-304.
10. Kraj M, Kruk B, Pogłód R. Clinical value of serum immunoglobulin free light chain quantification in multiple myeloma. Nowotwory J Oncol 2011; 61 (4): 52-58 (and pp. 355-362).
11. Kraj M, Kruk B, Pogłód R, et al. Correlation of serum immunoglobulin free light chain quantification with serum and urine immunofixation in monoclonal gammopathies. Acta Haematol Pol 2011; 42: 273-283.
12. Holding S, Spradbery D, Hoole R, et al. Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies. Clin Chem Lab Med 2011; 49: 83-88.
13. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011; 117: 4701-4705.
14. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215-224.
15. Kraj M, Kruk B, Lech-Marańda E, et al. High incidence of intact immunoglobulin or fragments thereof in urine of patients with multiple myeloma. Haematologica 2014; 99 (Suppl. 1): 378. Abstract P994.
16. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
17. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
18. Greipp PR, San Miguel J, Durie BGM, et al. International Staging System for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
19. Vervoort GH, Willems HL, Wetzels JF. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients; validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 2002; 17 (11): 1909-1913.
20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Inter Med 2009; 150: 604-612.
21. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437-1444.
22. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1684-1690.
23. Pogłód R, Kraj M, Kruk B, et al. Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma. Leuk Lymphoma 2010; 51: 2291-2294.
24. Tryggvason K, Wartiovaara J. How does the kidney filter plasma Physiology (Bethesda) 2005; 20: 91-101.
25. Russo LM, Sandoval RM, McKee M, et al. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int 2007; 71: 504-513.
26. Haymann JP, Levraud JP, Bouet S, et al. Characterisation and localisation of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol 2000; 11: 632-639.
27. Kobayashi N, Suzuki Y, Tsuge T, et al. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol 2002; 282: F358-F365.
28. Akilesh S, Huber TB, Wu H, et al. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci USA 2008; 105: 967-972.
29. Nowrousian MR, Brandhorst D, Sammet C, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11: 8706-8714.
30. Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002; 48: 655-657.
31. Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489-491.
32. Singhal S, Stein R, Vickrey E, et al. The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood 2007; 109: 3611-3612.
33. Siegel DS, MC Bride L, Bilotti E. Inaccuracies in 24-hour urine testing for monoclonal gammopathies. Serum free light chain analysis provides a more accurate measure of light chain burden than urine protein electrophoresis. Lab Medicine 2009; 40: 341-344.
34. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
35. Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007; 18: 886-895.
36. Herrera GA, Joseph L, Gu X, et al. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 2004; 128: 875-879.
37. Sanders PW, Booker BB, Bishop JB, et al. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest 1990; 85: 570-576.
38. Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992; 89: 630-639.
39. Basnayake K, Ying WZ, Wang PX, et al. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc Nephrol 2010; 21: 1165-1173.
40. Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 2008; 9: 11.
41. Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011; 22: 1129-1136.
42. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538-548.
43. Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2011; 8: 43-51.
44. Iwama KI, Chihara D, Tsuda K, et al. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma. Eur J Haematol 2012; 90: 134-141.
45. Drayson MT, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900-2902.
46. Dispenzieri A, Zhang I, Katzmann JA, et al. Appraisal of immunoglobulin free light chains as a marker of response. Blood 2008; 111: 4908-4915.